You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Invion Limited (IVX, formerly CBIO Limited) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has two key development programs: INV102 for inflammatory respiratory disease, and Chaperonin10 (CPN10) for the treatment of lupus. IVX also exploits the patented use of beta-2 adrenergic inverse agonism for the development of treatments for inflammatory conditions of the lungs such as asthma, chronic bronchitis and cystic fibrosis.
IMPORTANT: This information has been prepared without taking into account your objectives, financial situation or needs and you should consider if the information is appropriate for you before making an investment decision. Neither InvestSMART Financial Services Pty Ltd nor any of its Related Companies make any recommendations as to the merits of any investment opportunity referred to in its emails or its related websites. Product disclosure statements for financial products offered through InvestSMART can be downloaded from this website or obtained by contacting 1300 880 160. You should consider the product disclosure statement before making a decision about the product. All indications of performance returns are historical and can not be relied upon as an indicator for future performance.